Biocryst Pharmaceuticals (BCRX) Operating Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Operating Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -347.00 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -15,844.00 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -377.00 |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -204.00 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 7,045.00 |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -1,934.00 |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 9,003.00 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -2,825.00 |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -2.41 Mn |
| 10 | Biocryst Pharmaceuticals | 2.29 Bn | 1.94 Bn | 214.41 Mn | 7,021.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7,021.00 |
| Mar 31, 2026 | -40,724.00 |
| Dec 31, 2025 | 3.68 Mn |
| Sep 30, 2025 | 4,157.00 |
| Jun 30, 2025 | 7,122.00 |
| Mar 31, 2025 | 11,465.00 |
| Dec 31, 2024 | 10,722.00 |
| Sep 30, 2024 | 11,533.00 |
| Jun 30, 2024 | 6,723.00 |
| Mar 31, 2024 | 25,395.00 |
| Dec 31, 2023 | 125,922.00 |
| Sep 30, 2023 | 68,872.00 |
| Jun 30, 2023 | 131,625.00 |
| Mar 31, 2023 | 80,832.00 |
| Dec 31, 2022 | -5,795.00 |
| Sep 30, 2022 | 195,435.00 |
| Jun 30, 2022 | 235,848.00 |
| Mar 31, 2022 | 39,815.00 |
| Dec 31, 2021 | 81,504.00 |
| Sep 30, 2021 | 185,087.00 |